Get started
Author

Andrew D. Hecht

Observed names: Andrew Hecht, Hecht, Andrew D, Hecht, Andrew D.
ORCID: 0000-0002-9203-5950
Observed ORCID: 0000-0002-9203-5950
OpenAlex ID: A5067917508
Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors
2022 · Amanda M. Nash, Maria I. Jarvis, et al. · Science Advances · 79
Overlapping stimulons arising in response to divergent stresses in Escherichia coli
2021 · Huijing Wang, GW McElfresh, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
PDF
Effects of Chemical Modulators on Enzyme Specificity
2026 · Andrew D. Hecht, Oleg A. Igoshin · The Journal of Physical Chemistry B
PDF
Insights into Therapeutic Design via Kinetic Modeling
2025 · Hecht, Andrew D · Rice Research Repository (Rice University)
Kinetic Mechanism for Fidelity of CRISPR-Cas9 Variants
2025 · Andrew D. Hecht, Oleg A. Igoshin · The Journal of Physical Chemistry Letters
Favorable preclinical efficacy and safety profile of AVB-001, a novel IL-2 cell-based immunotherapy that eradicates ovarian cancer in mouse tumor models and supports first-in-human clinical development (1271)
2023 · Amir Jazaeri, Guillaume Carmona, et al. · Gynecologic Oncology
PDF
Signatures of antibiotic tolerance and persistence in response to divergent stresses
2023 · Huijing Wang, GW McElfresh, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Tumor Adjacent IL2 Cytokine Factories Eradicates Ovarian Cancer in Mice Through Cytotoxic T-cell Activation with Safe and Predictable Dosing in Non-human Primates
2022 · Guillaume Carmona, Amanda Nash, et al. · The Journal of Immunology
212 Tumor adjacent cytokine factories for eradication of ovarian cancer tumor burden in mice through cytotoxic T-cell activation with safe and predictable dosing in non-human primates
2021 · Amanda Nash, Maria Jarvis, et al. · Regular and Young Investigator Award Abstracts
PDF
Works count: 10
Citation count: 81
H-index: 2
I10-index: 1
Year
Topic
Type